Absci Corporation (ABSI) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Absci Corporation (ABSI) posted $2.80M in revenue for fiscal 2025 (down 38.2% year over year), with a net loss of $115.18M, and has compounded revenue about -10.1%/yr over five years, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Absci Corporation
Absci Corporation has grown revenue from $4.78M to $2.80M over the last 6 fiscal years, compounding about -10.1% a year. The most recent year was down 38.2%, so growth has cooled from its longer-run pace.
Net margin sits at -4113.7%, down 1839.6 points year over year. It carries about $873,000 of total debt.
It clears 1 of 6 deterministic health checks. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Absci Corporation's SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Absci Corporation? Check it against the filing
Open the full tool →Paste a headline number you saw about ABSI — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Absci Corporation revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.78M | $4.78M | $5.75M | $5.72M | $4.53M | $2.80M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-14.35M | $-100.96M | $-104.90M | $-110.57M | $-103.11M | $-115.18M |
| Net margin | -300.3% | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% |
Source: Absci Corporation SEC filings (10-K).
Absci Corporation financial health: 1 of 6 checks passed
- ✗Revenue CAGR over 5 yrs (-10.1%/yr)
- ✗Profitable every year (last 5)
- ✗Net margin above 10% (-4113.7%)
- ✓More cash than total debt (cash 144.3M vs debt 1.7M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Free cash flow positive (latest yr) (-94M)
Checks computed deterministically from filed annual statements — no AI judgement.
Absci Corporation: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 63.5% over 4 years (92.6M → 151.5M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $1.7M of debt while last year's operating cash flow was negative ($-92.9M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -4113.7%).
Explore 6 years of Absci Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track ABSI in your portfolio →
Absci Corporation financial history
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation — frequently asked questions
What is Absci Corporation's revenue?
Absci Corporation (ABSI) reported revenue of $2.80M for fiscal year 2025, down 38.2% from the prior year, according to its SEC filings.
Is Absci Corporation profitable?
No — ABSI reported a net loss of $-115.18M in fiscal 2025.
How fast is Absci Corporation growing?
ABSI's revenue grew at roughly -10.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Absci Corporation have?
As of fiscal year 2025, ABSI carried roughly $873,000 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Absci Corporation's market cap?
Absci Corporation (ABSI) has a market capitalization of about $986.88M, based on the latest data in our nightly-refreshed cache.
When does Absci Corporation's fiscal year end?
ABSI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Absci Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.